Apatinib exhibits anti-leukemia activity in preclinical models of acute lymphoblastic leukemia.

ABSTRACT: BACKGROUND:Acute lymphoblastic leukemia (ALL) is a clonal malignant disorder characterized by an uncontrolled proliferation of immature B or T lymphocytes. Extensive studies have suggested an involvement of angiogenesis signaling in ALL progression and resistance to treatment. Thus, targeting angiogenesis with anti-angiogenic drugs may be a promising approach for ALL treatment. In this study, we investigated the effectiveness of Apatinib, a novel receptor tyrosine kinase inhibitor selectively targeting VEGFR-2 in ALL cells. METHOD:ALL cell lines were treated with different concentration of Apatinib and then CCK8 assay, flow cytometry were used to determine the IC50 value and cell apoptosis, respectively. The effect of Apatinib against primary ALL cells from 11 adult patients and normal cou

SUBMITTER: Deng M 

PROVIDER: S-EPMC5831852 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature